Selective cyclooxygenase-2 (COX-2) inhibition reduces proteinuria in renal patients

Nephrology Dialysis Transplantation

Volumn 24, Issue 4, 2009, Pages 1182-1189

  Vogt, Liffert ^a,b,c   De Zeeuw, Dick ^a   Woittiez, Arend Jan J ^b   Navis, Gerjan ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b TWENTEBORG HOSPITAL   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Chronic renal failure; COX 2 inhibition; NSAID; Proteinuria; RAAS blockade

Indexed keywords

AMLODIPINE; CYCLOOXYGENASE 2; DOXAZOSIN; HYDROCHLOROTHIAZIDE; INDOMETACIN; LISINOPRIL; ROFECOXIB;

ADD ON THERAPY; ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; KIDNEY FUNCTION; MALE; MEAN ARTERIAL PRESSURE; OPEN STUDY; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SOMNOLENCE;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD PRESSURE; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INDOMETHACIN; KIDNEY; KIDNEY DISEASES; LACTONES; LISINOPRIL; MALE; MIDDLE AGED; PROTEINURIA; SULFONES;

EID: 65349156549     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn644     Document Type: Article

References (35)

1. Vogt L, Navis G, de Zeeuw D. Renoprotection: a matter of blood pressure reduction or agent-characteristics? J Am Soc Nephrol 2002; 13: S202-S207
2. de Zeeuw D, Remuzzi G, Parving H-H et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65: 2309-2320
3. Ruggenenti P, Perna A, Remuzzi G. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int2003; 63: 2254-2261
4. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal disease. Lancet 2001; 357: 1601-1608
5. Vogt L, Navis G, de Zeeuw D. Individual titration for maximal blockade of the renin-angiotensin system in proteinuric patients: a feasible strategy? J Am Soc Nephrol 2005; 16: S53-S57
6. Jafar TH, Stark PC, Schmid CH et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level metaanalysis. Ann Intern Med 2003; 139: 244-252
7. Donker AJM, Brentjens JR, Van Der Hem GK et al. Treatment of the nephrotic syndrome with indomethacin. Nephron 1978; 22: 374- 381
8. VriesendorpR,Donker AJM, de ZeeuwDet al. Effects of nonsteroidal anti-inflammatory drugs on proteinuria. Am J Med 1986; 81: 84- 94
9. Lagrue G, Laurent J, Belghiti D. Renal survival in membranoproliferative glomerulonephritis (MPGN): role of long-term treatment with non-steroid anti-inflammatory drugs (NSAID). Int Urol Nephrol1988; 20: 669-777
10. Heeg JE, de Jong PE, Van Der Hem GK et al. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989; 36: 272-279
11. Adams DH, Howie AJ, Michael J et al. Non-steroidal antiinflammatory drugs and renal failure. Lancet 1986; 1: 57-60
12. Arisz L, Donker AJM, Brentjens JR et al. The effect of indomethacin on proteinuria and kidney function in the nephrotic syndrome. Acta Med Scand 1976; 199: 121-125
13. Feldman M, McMahon AT. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann Intern Med 2000; 132: 134-143
14. Cheng HF, Harris RC. Cyclooxygenases, the kidney, and hypertension. Hypertension 2004; 43: 525-530
15. Vriesendorp R, de Zeeuw D, de Jong PE et al. Reduction of urinary protein and prostaglandin E2 excretion in the nephrotic syndrome by non-steroidal anti-inflammatory drugs. Clin Nephrol 1986; 25: 105- 110
16. Alavi N, Lianos EA, Venuto RC et al. Reduction of proteinuria by indomethacin in patients with nephrotic syndrome. Am J Kidney Dis1986; 8: 397-403
17. Bresalier RS, Sandler RS, Quan H et al. Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-1102
18. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 954- 959
19. Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin angiotensin system. Kidney Int 1994; 45: 861-867
20. Wang JL, Cheng HF, Shappell S et al. A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats. Kidney Int 2000; 57: 2334-2342
21. Cheng HF,Wang CJ, Moeckel GW et al. Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int 2002; 62: 929-939
22. Maschio G, Cagnoli L, Claroni F et al. ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: amulticentre, randomized, placebo-controlled study. Nephrol Dial Transplant 1994; 9: 265-269
23. Bos H, Andersen S, Rossing P et al. The role of patient factors in therapy resistance to antiproteinuric intervention in non-diabetic and diabetic nephropathy. Kidney Int 2000; 75: S32-S37
24. Heeg JE, de Jong PE, Vriesendorp R et al. Additive antiproteinuric effect of the NSAID indomethacin and the ACE inhibitor lisinopril. Am J Nephrol 1990; 10: S94-S97
25. Perico N, Remuzzi A, Sangalli F et al. The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. J Am Soc Nephrol 1998; 9: 2308-2317
26. Costanzi S, Sturniolo A, Fulignati P et al. Cyclooxygenase (COX)-2 selective inhibitors + ACE inhibitors: a new protocol in the treatment of heavy proteinuria. Nephrol Dial Transplant 2003; 18: 79A
27. Sinsakul M, Sika M, Rodby R et al. A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease. Am J Kidney Dis 2007; 50: 946-951
28. Apperloo AJ, de Zeeuw D, de Jong PE. Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int 1994; (Suppl 45): S174-S178
29. Rossat J, Maillard M, Nussberger J et al. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999; 66: 76-84
30. Sowers JR, White WB, Pitt B et al. The effects of cyclooxygenase- 2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005; 165: 161-168
31. Solomon DH, Schneeweiss S, Levin R et al. Relationship between COX-2 specific inhibitors and hypertension. Hypertension 2004; 44: 140-145
32. Esmatjes E, Levy I, Gaya J et al. Renal excretion of prostaglandin E2 and plasma renin activity in type I diabetes mellitus: relationship to normoglycemia achieved with artificial pancreas. Diabetes Care1987; 10: 428-431
33. Ordonez JD, Hiatt RA, Killebrew EJ et al. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 1993; 44: 638-642
34. Hillege HL, Fidler V, Diercks GF et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-1782
35. Mahmoodi BK, ten Kate MK, Waanders F et al. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation 2008; 117: 224-230